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Interactions of adriamycin with ferritin-bound iron have been investigated. It is demonstrated (i) that adria- 
mycin stimulates an iron-dependent lipid peroxidation in submitochondrial particles in the presence offer- 
ritin, and (ii) that incubation of adriamycin with ferritin results in a slow transfer of iron to adriamycin 
with formation of an adriamycin-iron complex. The results are discussed in relation to the possible role 
for intracellular iron in adriamycin toxicity. 
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1. INTRODUCTION 
Generation of reactive free radicals has been im- 
plicated as one of the factors that may contribute 
to the development of the special cardiotoxicity of 
adriamycin [l-4]. It is Well established from in 
vitro studies that adriamycin binds Fe3+ with con- 
siderable affinity [5,6], forming complexes which 
promote free radical-related amage to cell consti- 
tuents such as DNA [7] and membrane phospho- 
lipids [8,9]. It is, however, not’clear whether toxic 
adriamycin-iron complexes can form in vivo. Fer- 
ritin, the major storage of iron in cells [lO,l 11, is 
one possible intracellular source of iron for forma- 
tion of adriamycin-iron complexes. Heart tissue 
contains 30-60 pg ferritin protein/g [lo]. The fer- 
ritin molecule consists of a crystalline core of ferric 
oxyhydroxide, containing up to 4500 iron atoms, 
surrounded by a spherical protein shell, 150 A in 
diameter and about 25 A thick. Here we examine 
whether the affinity of adriamycin for iron is suffi- 
cient to allow transfer of ferritin-bound iron to 
adriamycin. 
carried out in 150 mM KCl, 50 mM Tris-HCl buf- 
fer (pH 7.4) at 30°C in the dark. Samples were 
removed from the incubation mixtures at intervals 
and adriamycin-Fe3+ complex was determined 
spectrophotometricahy at 600 nm in 1 cm light- 
path cuvettes. The absorptions at 600 nm of 
adriamycin and ferritin, incubated separately, 
were subtracted from the measurements. 
2.2. Determination of ferritin iron released by 
ADP 
Release of ferritin iron in ADP containing in- 
cubation buffer without adriamycin was assayed 
by adding 10 ~1 10 mM bathophenanthroline di- 
sulphonate and 10~1 10 mM ascorbic acid to 1 ml 
samples. The concentration of ‘free’ iron was 
calculated from the increase in absorbance at 534 
nm obtained after 2 min using 6 = 22 140 
M-‘-cm-’ [12]. 
2.3. Other methods 
2. MATERIALS AND METHODS 
2.1. Conditions for determining transfer of 
ferritin iron to adriamycin 
Incubations of ferritin with adriamycin were 
Submitochondrial particles were prepared from 
pig heart mitochondria as described in [9] but us- 
ing 250 mM sucrose in the buffers instead of 150 
mM KCI. 
Measurements of NADH oxidase activity in sub- 
mitochondrial particles incubated together with 
ferritin and adriamycin, protein determination, ex- 
traction of particle phospholipid, fatty acid ana- 
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lysis by GLC and determination of adriamycin and 
FeCL stock solutions were carried out as described 
previously j9). Total ferritin iron was determined 
by the method described in [ 131. 
Stability of adriamycin during incubation was 
assessed by thin-layer chromatography (TLC) on 
0.25 mm silica gel plates (Merck, Darmstadt, FRG) 
using the solvent chloroform/methanol/acetic acid 
(46: 15:6, v/v). 
2.4. Materials 
Ferritin (from horse spleen, cadmium-free and 3 
x crystallized) and ADP were from Boehringer 
(Mannheim, FRG). Bathophenanthroline disul- 
phonate was from Sigma (St. Louis, USA). Adria- 
mycin/HCl was a gift from Farmitalia Carlo Erba 
(Milano, Italy). 
Buffer solutions were prepared from analytical 
grade reagents the day before use with water 
purified by ion exchange in a Millipore system 
(Millipore). 
3. RESULTS 
Adriamycin-iron complexes support perox- 
idative damage to respiratory chain activity and 
phospholipids in submitochondrial particles [9, 
141. When submitochondrial particles were in- 
cubated with horse spleen ferritin (50 pg/rnl cor- 
responding to 1% pM ferritin iron) about 30% of 
their NADH oxidase activity was lost during a 3-h 
period. Inclusion of adriamycin into the incuba- 
tion mixtures caused a drastic increase in the rate 
of inactivation as shown in fig. 1. Also, accelerated 
peroxidative breakdown of polyunsaturated fatty 
acid moieties of phospholipids in the particles in- 
cubated with ferritin was measured upon addition 
of adriamycin to the incubation mixtures (table 1). 
Both NADH oxidase activity and phospholipids 
were protected in the presence of 1 mM EDTA. 
Spectrophotometric determination of adria- 
mycin-Fe’+ complex formed during the incubation 
of ferritin with adriamycin was carried out using 
absorption of the complex at 600 nm [15]. 600 nm 
absorbing material was found to develop with time 
in incubation mixtures containing ferritin (50 
pg/ml) together with adriamycin (25-200 &I) (not 
shown). However, a visible colloid appeared dur- 
ing the incubations and it could not be excluded 
98 
_ loo- 
1 
.$ 50- 
.- 
‘6 
$ 
a 
.Z 
..z lo- 
o 
1 5- 
‘iz 
i 95 
s 
L 
'OI 
Time (h) 
Fig. 1. Inhibition of NADH oxidase activity in pig heart 
submitochondrial particles by adriamycin during in- 
cubation with ferritin. Particle protein (94 ,ug/ml), fer- 
ritin (50 /cg/ml) and adriamycin (O-95 CM). 
Table 1 
Loss in phospholipid arachidonic acid and NADH ox- 
idase activity of submitochondrial particles incubated 
with adriamycin and ferritin 
Incubation 
conditions 
Arachidonic acid NADH oxidase 
in particle lipid activity 
(olo of control) 
Adriamycin 
Ferritin 
Adriamycin + 
ferritin 
+ EDTA (1 mM) 
91.3 89.4 
76.5 69.1 
20.2 4.7 
72.1 92.0 
Particle protein (86pg/ml), adriamycin (50tM), ferritin 
(50 #g/ml). Incubation period was 3 h and control par- 
ticles were incubated in the absence of adriamycin and 
ferritin 
that part of the measured increase in 600 run absor- 
bance was due to light scattering in the cuvettes. 
We found that colloid formation could be prevent- 
ed by 1 mM ADP and the incubations of ferritin 
with adriamycin were therefore repeated in ADP- 
containing buffer. Results are given in fig.2. It is 
seen that 600 nm absorbing material also formed 
under these conditions and at a rate that increased 
with adriamycin concentration. No increase in 600 
nm absorbance was measured when 1 mM EDTA 
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Fig. 2. Iron transfer from ferritin to adriamycin. Ferritin 
(50pg/ml) and adriamycin (O-200,uM) were incubated in 
buffer containing 1 mM ADP. Values represent the 
mean of 3 separate xperiments. Bars are SE. (---), 
release of ferritin iron in the absence of adriamycin. 
was added to the incubation mixtures or when 
adriamycin and ferritin were incubated separately 
(not shown). 
Addition of Fe3+ (as a freshly prepared 1 mM 
FeCls in 1 mM HCl) to adriamycin in ADP- 
containing buffer was found to result in a rapid 
formation of adriamycin-Fe3+ complex (within 
less than 1 min) and the obtained 600 nm absor- 
bance was a linear function of the Fe3+ concentra- 
tion up to 10 pM. A molar absorption coefficient 
of 9700 M-’ a cm-’ was calculated, which is close 
to the value of 11400 found by authors in 1151 in 
buffer containing acetohydroxamic acid. The ab- 
sorbance measurements in fig.2 could therefore be 
taken as a direct measure for the concentration of 
iron released from ferritin as given by the second 
ordinate. The 4 /rM iron released during the 6-h in- 
cubation period corresponds to 2% of the total 
iron in the ferritin. 
ADP alone can release ferritin-bound iron and 
the progress curves for fo~ation of adriamycin- 
Fe3+ complex in fig.2 can be expected to express 
the sum of iron release by ADP and adriamycin. 
The contribution from ADP was estimated using 
the iron, chelator bathophenanthroline disulphon- 
ate during incubation of ferritin in ADP contain- 
ing buffer without adriamycin (see section 2.2.). 
The results are given by the dotted line in fig.2. 
4. DISCUSSION 
We conclude from the above results that 
ferritin-bound iron can be transferred to adria- 
mycin and that the adriamycin-iron complexes 
formed support peroxidative damage to membrane 
lipids and enzyme activities. 
It is well documented that ferritin iron can be 
released by iron chelators [16,17] and by reducing 
agents such as ascorbate, thiols and ~hydro~avins 
(reduced riboflavin, FMNHz, FMNHz) [18-221. It 
has also been demonstrated [23,24J, that ferritin in 
the presence of ascorbate can serve as source of 
iron in lipid peroxidation reactions. Adriamycin 
has iron binding as well as reducing properties, 
possibly owing to its quinone-hydroquinone struc- 
ture [25], and the size of the molecule is probably 
small enough (similar to that of FADHz) to have 
direct access to the iron core of ferritin through the 
pores of the protein shell. The biphasic time course 
for formation of ad~~ycin-Fe3+ complex may be 
explained by the presence of a small fraction of 
iron contained in the ferritin molecule in a loosely 
bound form [20]. 
Cells, also myocardial cells, are able to take up 
large amounts of adriamycin [26-281, but little in- 
formation is available on its intracellular routing. 
The present data suggest that adriamycin-iron 
complexes could form, resulting in damage to cell 
components ensitive to free radical attack. Studies 
on cultured cells with a varied iron-loading and 
ferritin content [29,30] could contribute with 
valuable results in regard to the possible role for 
intracellular iron in adriamycin toxicity. 
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